nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A disease activity index: Its use in clinical trials and disease assessment in patients with rheumatoid arthritis
|
Davis, M.J. |
|
1993 |
|
2S1 |
p. 50-56 7 p. |
artikel |
2 |
A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: An interim report on 102 patients after 12 months
|
Rau, R. |
|
1991 |
|
2S1 |
p. 13-20 8 p. |
artikel |
3 |
Analgesic effects of prostaglandin synthesis inhibition by diclofenac sodium
|
Kral, John G. |
|
1985 |
|
2S1 |
p. 93-96 4 p. |
artikel |
4 |
An editor's liaison with indomethacin
|
Talbott, John H. |
|
1982 |
|
2S1 |
p. 97-99 3 p. |
artikel |
5 |
Antiinflammatory activity of indomethacin in clinical practice
|
Hart, F.Dudley |
|
1982 |
|
2S1 |
p. 103-104 2 p. |
artikel |
6 |
Antiinflammatory therapy: Pre-indomethacin
|
Rothermich, Norman O. |
|
1982 |
|
2S1 |
p. 81-84 4 p. |
artikel |
7 |
Appraisal of efficacy and tolerability of INDOCIN® (Indomethacin, MSD) in acute gout and moderate to severe ankylosing spondylitis
|
Calabro, John J. |
|
1982 |
|
2S1 |
p. 112-116 5 p. |
artikel |
8 |
Clinical application of indomethacin: Efficacy and tolerability
|
Plotz, Charles M. |
|
1982 |
|
2S1 |
p. 100-102 3 p. |
artikel |
9 |
Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic example
|
Furst, Daniel E. |
|
1993 |
|
2S1 |
p. 57-61 5 p. |
artikel |
10 |
Compliance
|
Katz, Warren A. |
|
1982 |
|
2S1 |
p. 132-135 4 p. |
artikel |
11 |
Current concepts in the rheumatic diseases: Etiology and treatment
|
Hart, Francis Dudley |
|
1985 |
|
2S1 |
p. 4-7 4 p. |
artikel |
12 |
Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine
|
Iredale, Joanna |
|
1993 |
|
2S1 |
p. 74-81 8 p. |
artikel |
13 |
Diclofenac in the treatment of ankylosing spondylitis: Review of worldwide clinical experience and report of a double-blind comparison with indomethacin
|
Khan, Muhammad Asim |
|
1985 |
|
2S1 |
p. 80-84 5 p. |
artikel |
14 |
Diclofenac in the treatment of painful joints and traumatic tendinitis (including strains and sprains): A brief review
|
Machtey, Israel |
|
1985 |
|
2S1 |
p. 87-92 6 p. |
artikel |
15 |
Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis
|
Caldwell, Jacques R. |
|
1985 |
|
2S1 |
p. 73-79 7 p. |
artikel |
16 |
Early, aggressive therapy for rheumatoid arthritis: Concerns, descriptions, and estimate of outcome
|
Wilke, William S. |
|
1993 |
|
2S1 |
p. 26-41 16 p. |
artikel |
17 |
Evaluation of sustained-release indomethacin in osteoarthritis
|
Gengos, Don C. |
|
1982 |
|
2S1 |
p. 142-146 5 p. |
artikel |
18 |
INDOCIN® SR (Indomethacin, MSD) in the treatment of moderate to severe rheumatoid arthritis
|
Hart, C.B. |
|
1982 |
|
2S1 |
p. 147-151 5 p. |
artikel |
19 |
Indomethacin and indomethacin sustained release—A comparison of their pharmacokinetic profiles
|
Yeh, Kuang C. |
|
1982 |
|
2S1 |
p. 136-141 6 p. |
artikel |
20 |
Indomethacin in acute painful shoulder bursitis and/or tendinitis
|
Calabro, John J. |
|
1982 |
|
2S1 |
p. 130-131 2 p. |
artikel |
21 |
Indomethacin in the 1970s
|
Stevenson, Carl R. |
|
1982 |
|
2S1 |
p. 107-108 2 p. |
artikel |
22 |
Introduction
|
Rothermich, Norman O. |
|
1982 |
|
2S1 |
p. 77- 1 p. |
artikel |
23 |
Introduction
|
Paulus, Harold E. |
|
1993 |
|
2S1 |
p. 1- 1 p. |
artikel |
24 |
Introduction: The art and science of nonsteroidal anti-inflammatory drug selection
|
Gottlieb, Norman L. |
|
1985 |
|
2S1 |
p. 1-3 3 p. |
artikel |
25 |
Introduction: The place of methotrexate in the treatment of rheumatoid arthritis
|
Hoffmeister, Rex T. |
|
1991 |
|
2S1 |
p. 1-3 3 p. |
artikel |
26 |
Inverting the therapeutic pyramid: Observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience
|
Wilske, Kenneth R. |
|
1993 |
|
2S1 |
p. 11-18 8 p. |
artikel |
27 |
Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases
|
Pincus, Theodore |
|
1993 |
|
2S1 |
p. 2-10 9 p. |
artikel |
28 |
Long-term experience with indomethacin in active stages of moderate to severe rheumatoid arthritis and moderate to severe osteoarthritis
|
Lockie, L.Maxwell |
|
1982 |
|
2S1 |
p. 109-111 3 p. |
artikel |
29 |
Marine sponge aggregation: A model for effects of NSAIDs on the calcium movements of cell activation
|
Weissmann, Gerald |
|
1985 |
|
2S1 |
p. 42-53 12 p. |
artikel |
30 |
Mechanism of action of hydroxychloroquine as an antirheumatic drug
|
Fox, Robert I. |
|
1993 |
|
2S1 |
p. 82-91 10 p. |
artikel |
31 |
Mechanisms of cartilage degradation: Relation to choice of therapeutic agent
|
Cooke, Theodore Derek Vernon |
|
1985 |
|
2S1 |
p. 16-23 8 p. |
artikel |
32 |
Panel discussion I
|
|
|
1985 |
|
2S1 |
p. 14-15 2 p. |
artikel |
33 |
Panel Discussion II
|
|
|
1985 |
|
2S1 |
p. 54-56 3 p. |
artikel |
34 |
Panel discussion III
|
|
|
1985 |
|
2S1 |
p. 85-86 2 p. |
artikel |
35 |
Panel Discussion IV
|
|
|
1985 |
|
2S1 |
p. 97-98 2 p. |
artikel |
36 |
Pathogenesis of osteoarthritis and use of diclofenac in the treatment of experimental models
|
Pelletier, Jean-Pierre |
|
1985 |
|
2S1 |
p. 24-28 5 p. |
artikel |
37 |
Pathogenesis of rheumatoid arthritis: Basis for future therapies
|
Wortmann, Robert L. |
|
1991 |
|
2S1 |
p. 35-39 5 p. |
artikel |
38 |
Personal experience in the treatment of seropositive rheumatoid arthritis with drugs used in combination
|
McCarty, Daniel J. |
|
1993 |
|
2S1 |
p. 42-49 8 p. |
artikel |
39 |
Pharmacology of diclofenac sodium (Voltaren®)
|
Scholer, Dietrich W. |
|
1985 |
|
2S1 |
p. 61-64 4 p. |
artikel |
40 |
Prognostic staging for therapy of rheumatoid arthritis
|
Willkens, Robert F. |
|
1991 |
|
2S1 |
p. 40-43 4 p. |
artikel |
41 |
Prostaglandin research: Clinical implications
|
Kuehl, Jr., Frederick A. |
|
1982 |
|
2S1 |
p. 119-125 7 p. |
artikel |
42 |
Prostaglandins, thromboxanes, and leukotrienes in inflammation
|
Malmsten, Curt L. |
|
1985 |
|
2S1 |
p. 29-35 7 p. |
artikel |
43 |
Protocol development for combination therapy with disease-modifying antirheumatic drugs
|
Paulus, Harold E. |
|
1993 |
|
2S1 |
p. 19-25 7 p. |
artikel |
44 |
Special studies of diclofenac and safety: Gastrointestinal, renal, hepatic, and other consequences of therapy
|
Roth, Sanford H. |
|
1985 |
|
2S1 |
p. 99-104 6 p. |
artikel |
45 |
Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis
|
Benson, Merrill D. |
|
1985 |
|
2S1 |
p. 65-67 3 p. |
artikel |
46 |
The advent of INDOCIN® (Indomethacin, MSD): Impact on clinical medicine
|
Smyth, Charley J. |
|
1982 |
|
2S1 |
p. 94-96 3 p. |
artikel |
47 |
The discovery of indomethacin and the proliferation of NSAIDs
|
Shen, T.Y. |
|
1982 |
|
2S1 |
p. 89-93 5 p. |
artikel |
48 |
The effects of diclofenac sodium on arachidonic acid metabolism
|
Ku, Edmond C. |
|
1985 |
|
2S1 |
p. 36-41 6 p. |
artikel |
49 |
The history of diclofenac
|
Sallmann, Alfred R. |
|
1985 |
|
2S1 |
p. 57-60 4 p. |
artikel |
50 |
The immunologic basis of chronic inflammatory disease
|
Rosenthal, Alan S. |
|
1982 |
|
2S1 |
p. 126-129 4 p. |
artikel |
51 |
The ocular safety of hydroxychloroquine
|
Easterbrook, Michael |
|
1993 |
|
2S1 |
p. 62-67 6 p. |
artikel |
52 |
Therapeutic significance of laboratory results in rheumatic disease
|
Wright, Verna |
|
1985 |
|
2S1 |
p. 8-13 6 p. |
artikel |
53 |
Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment
|
Wilke, William S. |
|
1991 |
|
2S1 |
p. 21-34 14 p. |
artikel |
54 |
The relative toxicity of alternative therapies for rheumatoid arthritis: Implications for the therapeutic progression
|
Fries, James F. |
|
1993 |
|
2S1 |
p. 68-73 6 p. |
artikel |
55 |
The search for antiinflammatory activity
|
Winter, C.A. |
|
1982 |
|
2S1 |
p. 85-88 4 p. |
artikel |
56 |
Worldwide clinical safety experience with diclofenac
|
Willkens, Robert F. |
|
1985 |
|
2S1 |
p. 105-110 6 p. |
artikel |
57 |
Worldwide experience with diclofenac in rheumatoid arthritis and osteoarthritis
|
Macauley, David |
|
1985 |
|
2S1 |
p. 68-72 5 p. |
artikel |
58 |
Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis
|
Markenson, Joseph A. |
|
1991 |
|
2S1 |
p. 4-12 9 p. |
artikel |